COLL Q1 2021 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$88M+14.7% YoY

Gross Profit

$56M63.4% margin

Operating Income

$21M24.2% margin

Net Income

$16M17.9% margin

EPS (Diluted)

$0.41

QoQ Revenue Growth

+15.0%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

$20M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$646M

Total Liabilities

$476M

Stockholders' Equity

$170M

Cash & Equivalents

$183M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$88M	$77M	+14.7%
Gross Profit	$56M	$39M	+42.6%
Operating Income	$21M	$5M	+318.7%
Net Income	$16M	$450,000	+3380.4%

Revenue Segments

Nucynta

$52M37%

Xtampza

$35M25%

Nucynta Ir

$31M22%

Nucynta Er

$22M16%